Abstract
Behavioral and psychotic disturbances are common symptoms in neurodegenerative disorders, and can lead to caregiver stress, nursing home placement and mortality. There is an expanding literature evaluating the effects of atypical antipsychotic (AA) drugs for treating these problems. The results in both primary dementias and Parkinson’s disease suggest that not all AA drugs are equal in terms of efficacy or safety. Furthermore, Parkinsonian and other side effects of the AAs are important to consider when evaluating outcomes. The recent US FDA warning of increased mortality has increased uncertainty in using these drugs. This article reviews the AAs and their use in Parkinson’s disease, dementia with Lewy bodies, Alzheimer’s disease and other associated dementias.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
